...
首页> 外文期刊>BMC Public Health >Efficacy of indoor air purification in treating Artemisia (mugwort) pollen allergic rhinitis: study protocol for a randomised controlled trial
【24h】

Efficacy of indoor air purification in treating Artemisia (mugwort) pollen allergic rhinitis: study protocol for a randomised controlled trial

机译:室内空气净化在治疗Artemisia(Mugwort)花粉过敏鼻炎的功效:随机对照试验的研究方案

获取原文
           

摘要

Allergic rhinitis (AR) is a worldwide health problem. Allergen avoidance is strongly recommended for AR patients. Air purification can reduce concentrations of particles in indoor air, including those of allergens. Air purifiers have been recommended by clinicians for AR patients, but few studies have focused on the removal of airborne allergens from home environments. Such studies have been limited by a lack of blinding, small samples, or a failure to measure allergen levels, disease activity, or a combination of these factors. This study investigates the efficacy of a high-efficiency air purifier in reducing disease activity in the homes of AR patients sensitive to the allergens produced by Artemisia (mugwort) pollen. This is a randomized, double-blind, clinical controlled trial that will test active and inactive versions of an air purifier (Atmosphere?; Amway China). Sixty AR patients sensitive to the allergens produced by Artemisia pollen will be assigned randomly to two groups of equal numbers. All patients will undergo a 4-week treatment period and a 4-week observation period. Evaluation will be conducted at baseline (day 0) and on days 7, 14, 21, 28, and 56. The primary outcome measure will be the difference in visual analog scale scores from baseline. Secondary outcomes will be changes from baseline in nasal symptoms, allergy symptom scores, responses to the Rhinoconjunctivitis Quality of Life Questionnaire, Epworth Sleepiness Scale scores, and tolerability scores for the air purifier. Side effects of treatment will be recorded. Reducing exposure to allergens can reduce the risk of conditions such as AR. We hypothesise that AR patients sensitive to the allergens produced by Artemisia pollen will not suffer symptoms in a pollen-free environment. AR patients can remove pollen from their homes using air purifiers, decreasing the risk of symptoms. We expect that our study results will provide reliable evidence for determining the effects of air-purification therapy. ChiCTR-INR-17012481 . (Retrospectively registered 26 August 2017).
机译:过敏性鼻炎(AR)是全球健康问题。强烈推荐用于AR患者的过敏原避免。空气净化可以减少室内空气中的颗粒的浓度,包括过敏原。 AR患者的临床医生推荐了空气净化器,但很少有研究专注于从家庭环境中去除空气过敏原。这些研究受到盲目,小样品或未能测量过敏原水平,疾病活动或这些因素的组合的限制。本研究研究了高效空气净化器在敏感过敏原子患者的患者中减少疾病活动的疗效,以艾蒿(Mugwort)花粉敏感。这是一项随机的双盲,临床对照试验,将测试有效和无效的空气净化器(大气的临床版本(大气)?六十ar对Artemisia Pollen产生的过敏原敏感的患者将随机分配给两组相等的数量。所有患者将经历4周的治疗期和4周的观察期。评估将在基线(第0天)和第7,14,21,28,28和56天进行。主要结果措施将是基线视觉模拟规模评分的差异。二次结果将从鼻症状,过敏症状评分的基线变化,对鼻咽炎的抗鼻咽炎质量的反应问卷,欧克斯睡眠尺度评分和空气净化器的可耐受性分数。将记录治疗的副作用。减少过敏原的暴露可以降低诸如AR等条件的风险。我们假设对Artemisia Pollen产生的过敏原敏感的AR患者不会在无污染环境中遭受症状。 AR患者可以使用空气净化器从家中取出花粉,降低症状的风险。我们预计我们的研究结果将提供可靠的证据来确定空气纯化治疗的影响。 CHICTR-INR-17012481。 (回顾2017年8月26日)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号